Equities Analysts Issue Forecasts for AxoGen FY2028 Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Analysts at Leerink Partnrs lowered their FY2028 EPS estimates for shares of AxoGen in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will earn $0.12 per share for the year, down from their previous estimate of $0.13. The consensus estimate for AxoGen’s current full-year earnings is ($0.33) per share.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. The company had revenue of $47.91 million for the quarter, compared to analysts’ expectations of $43.27 million.

Other research analysts have also issued reports about the stock. JMP Securities lifted their price objective on shares of AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research note on Friday, August 9th. Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 price target on shares of AxoGen in a report on Thursday, June 20th. Raymond James assumed coverage on AxoGen in a report on Monday, July 1st. They set an “outperform” rating and a $13.00 price objective for the company. Finally, StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, AxoGen currently has a consensus rating of “Buy” and a consensus target price of $15.00.

AxoGen Stock Performance

NASDAQ AXGN opened at $13.24 on Friday. The business’s 50 day moving average price is $13.26 and its 200-day moving average price is $9.40. AxoGen has a fifty-two week low of $3.45 and a fifty-two week high of $15.23. The company has a market cap of $578.65 million, a P/E ratio of -26.48 and a beta of 1.13. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.32 and a current ratio of 3.51.

Hedge Funds Weigh In On AxoGen

Several institutional investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in AxoGen in the third quarter worth about $56,000. Koss Olinger Consulting LLC purchased a new position in AxoGen during the 2nd quarter valued at about $75,000. Lazard Asset Management LLC raised its holdings in shares of AxoGen by 30.1% in the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 2,671 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of AxoGen in the 2nd quarter worth approximately $125,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of AxoGen by 8.6% during the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after purchasing an additional 1,651 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.